Market News AIOpen the app

Mirum Pharmaceuticals is starting a new study for zilurgisertib in kids with a rare bone disease.

TrialRead the original at milanofinanza.it
Good for MIRM

Mirum added a study of zilurgisertib in children ages 2 to 12 years, building on earlier results showing fewer new bone-growth spots than placebo. The child study has no results yet, but the earlier findings make this a positive step.

MIRM · Mirum Pharmaceuticals

AI read · Good for MIRM

The AI's read

The earlier results give Mirum a reason to test the drug in younger patients. Fewer new bone-growth spots than placebo suggests it may help people with FOP. The new study has not reported results, so benefit in children is not yet shown.

Get alerts for MIRM

Follow Mirum Pharmaceuticals (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MIRM
Free on the App Store and Google Play, or on the web.